English 
CMIC Co., Ltd., a contract research organization jointly owned by Blackstone and CMIC HOLDINGS, has entered a strategic partnership with Bluenote to bring agentic AI into clinical development operations. The focus is pretty clear. Reduce the time and effort that goes into regulatory and clinical documentation, which has long been one of the slowest and most resource heavy parts of drug development.
Bluenote’s platform employs agentic AI technology to manage all documentation requirements throughout the entire clinical development process. The system requires management of various documents which include protocols statistical analysis plans clinical study reports eCTD modules and CMC documentation. The system is built to align with global regulatory frameworks including ICH, FDA, PMDA, and EMA requirements. The system provides traceability to original data together with validation safeguards and automated quality assessment which enables documents to progress more quickly while maintaining compliance standards.
CMIC plans to integrate these AI agents across its broader clinical development workflows rather than using AI as a one off tool. The company has more than three decades of experience as one of Japan’s largest CROs and works with pharmaceutical and emerging biopharma companies across the Asia Pacific region and globally.
こちらもお読みください： Astella社とVir Biotechnology社がVIR-5500のグローバル契約を締結
CMIC reports that the integration will accelerate certain regulatory and clinical documentation processes by up to 75 percent. The industry benefits from this efficiency because it enables faster progress through drug trials which typically take multiple years to complete.
日本語